Targeting ROCK/LIMK/cofilin signaling pathway in cancer.

Lee, Mee-Hyun; Kundu, Joydeb Kumar; Chae, Jung-Il; Shim, Jung-Hyun

Lee, Mee-Hyun; Kundu, Joydeb Kumar; Chae, Jung-Il; Shim, Jung-Hyun.

Affiliation

Lee MH; Basic Medical College, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Kundu JK; China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
Chae JI; Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, AB, T6G 2R3, Canada.
Shim JH; Department of Dental Pharmacology, School of Dentistry, BK21 Plus, Chonbuk National University, Chonju, 54896, Republic of Korea.

Arch Pharm Res ; 42(6): 481-491, 2019 Jun.

Article in En | MEDLINE | ID: mdl-31030376

Subject(s)

Antineoplastic Agents/pharmacology; Neoplasms/drug therapy; Protein Kinase Inhibitors/pharmacology; Signal Transduction/drug effects; Actin Depolymerizing Factors/antagonists & inhibitors; Actin Depolymerizing Factors/metabolism; Animals; Antineoplastic Agents/therapeutic use; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lim Kinases/antagonists & inhibitors; Lim Kinases/metabolism; Molecular Targeted Therapy/methods; Neoplasms/pathology; Phosphorylation/drug effects; Protein Kinase Inhibitors/therapeutic use; rho-Associated Kinases/antagonists & inhibitors; rho-Associated Kinases/metabolism

Key words

Cancer therapy; Cofilin; Inhibitors; LIMK; ROCK; Signaling pathways

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Signal Transduction / Protein Kinase Inhibitors / Neoplasms / Antineoplastic Agents Language: En Journal: Arch Pharm Res Year: 2019 Type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google